Shares of biotechnology company United Therapeutics (NASDAQ:UTHR)
fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations, overshadowing an earnings beat.
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company cemented its status as a high-performance healthcare powerhouse by reporting a significant Q4 2025 earnings beat and officially surpassing the $3 billion annual revenue milestone for [...]
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share was 14% above analysts’ consensus estimates.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United Therapeutics (NASDAQ:UTHR).
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns,
and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
One value-focused hedge fund just doubled down on one of North America’s biggest coal exporters — here’s what that could mean for the stock’s next chapter.
United Therapeutics (UTHR) presents a compelling value investment case with strong profitability, a debt-free balance sheet, and a valuation discounted relative to its biotech sector peers.
United Therapeutics (UTHR) excels as a Caviar Cruise quality stock with strong growth, high profitability, a debt-free balance sheet, and exceptional returns on capital.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
